

Bit Market Services

Informazione Regolamentata n. 0472-32-2016	Data/Ora Ricezione 11 Luglio 2016 18:14:53	MTA - Star
--	--	------------

Societa' : BB BIOTECH

Identificativo : 76887

Informazione
Regolamentata

Nome utilizzatore : BIOTECHNSS01 - Alderuccio

Tipologia : IRAG 10

Data/Ora Ricezione : 11 Luglio 2016 18:14:53

Data/Ora Inizio : 11 Luglio 2016 18:29:54

Diffusione presunta

Oggetto : BB Biotech AG with after-tax loss in the first
half year of 2016

Testo del comunicato

Vedi allegato.

Media Release, July 11, 2016

BB Biotech AG with after-tax loss in the first half year of 2016

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for the first half year of 2016.

Based on preliminary unaudited consolidated results, BB Biotech AG closed the first half year of 2016 with a loss of CHF 1.17 billion (CHF 717 million profit in the corresponding period of the previous year).

BB Biotech's share price decreased 18.8% in CHF and 18.4% in EUR during the corresponding period.

Biotechnology stocks and BB Biotech AG's portfolio stabilized in the second quarter of 2016. BB Biotech earned an after-tax profit of CHF 36 mn in the second quarter (profit of CHF 337 mn in prior-year period). As an investment company, the results reflect the performance of the stocks it holds in its investment portfolio.

The interim report as of June 30, 2016 will be published on July 22, 2016.

For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch

www.bbbiotech.com

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world's largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech's investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.

Fine Comunicato n.0472-32

Numero di Pagine: 3